Related Experiment Videos
Buffy coat transfusions in early type I diabetes
J Cavanaugh1, M Chopek, J Binimelis
1Department of Medicine, University of Minnesota, Minneapolis.
Diabetes
|October 1, 1987
Summary
Whole-blood buffy coats showed potential in treating early type I diabetes, with two patients achieving temporary remission. Further research is needed to optimize this adoptive immunotherapy approach.
Area of Science:
- Immunology
- Endocrinology
- Hematology
Background:
- Type I diabetes is an autoimmune disease characterized by pancreatic beta-cell destruction.
- Current treatments focus on insulin replacement and glycemic control.
- Rodent models have shown promise for adoptive immunotherapy in diabetes.
Purpose of the Study:
- To evaluate the efficacy of whole-blood buffy coat transfusions in early-stage type I diabetes.
- To adapt a successful rodent protocol for human application.
Main Methods:
- Twenty-two patients with early type I diabetes were randomized into treatment and control groups.
- Treatment group received weekly buffy coat transfusions (T-lymphocytes) for 5 weeks.
- Plasma C-peptide, insulin dose, and hemoglobin A1c were monitored for 24 weeks.
Main Results:
- No significant differences in key parameters were observed between groups.
- Two out of 12 patients in the treatment group achieved temporary complete remission (normal glycemia without insulin).
- One patient experienced a second remission after a relapse and a second transfusion course.
Conclusions:
- Whole-blood buffy coat transfusion may offer a potential avenue for inducing remission in early type I diabetes.
- Limitations in the current protocol may explain the limited success compared to rodent studies.
- Further investigation into adoptive immunotherapy for diabetes treatment and prevention is warranted.